Founded in 2020, Mestag Therapeutics’ vision is to transform the lives of people affected by inflammatory disease and cancer, addressing unmet needs through a unique understanding of fibroblast populations.
Single cell data shows that fibroblast populations play an important role in influencing immune effector cells in disease. Mestag’s founders have helped shape a new understanding of fibroblast populations, identifying exciting new biology and opening up new therapeutic approaches.
Mestag Therapeutics closed an oversubscribed seed round extension in August 2021 to take the total to $45 million. The extension of $34m was led by Amsterdam-based investment firm Forbion together with global healthcare investors GV (formerly Google Ventures) and Northpond Ventures and supported by founding investors SV Health Investors, and Johnson & Johnson Innovation.
In May 2021 Mestag agreed a target discovery, option and licence agreement with Janssen Biotech, Inc. – one of the Janssen Pharmaceutical Companies of Johnson & Johnson.